{"transactions":[{"id":1138971,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":240,"expiration_date":"2027-10-12","underlying":"Common Stock","underlying_shares":1925},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138970,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":962,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":337.5,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":962},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138969,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":962,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":99,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":962},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138968,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":962,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":84.75,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":962},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138967,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":962,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":53.1,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":962},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138966,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2133,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":29.25,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":2133},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138965,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":17.7,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":3566},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1138964,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:25:49.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":15.6,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-25-051346","document":"tm2515648-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051346/tm2515648-9_4seq1.xml","form_type":"4"}},{"id":1439626,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-08-06T20:21:21.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1055,"price":12.24,"value":12913.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2024 through June 30, 2024.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024."}],"balance_after":252290,"source":{"system":"sec-edgar","filing":"0001562180-24-006042","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024006042/primarydocument.xml","form_type":"4"}},{"id":1486745,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-06-07T20:06:56.000Z","date":"2024-06-05","kind":"exercise","planned":false,"acquired":false,"shares":124373,"price":22.82,"value":2838191.86,"ownership":{"direct":false,"nature":"The 2020 Groenhuysen Annuity Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to buy 219,372 ordinary shares will vest in equal installments on each of February 22, 2018, 2019 and 2020, subject to the reporting person's continued employment through such dates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership."}],"balance_after":95000,"derivative":{"exercise_price":7.15,"expiration_date":"2027-02-21","underlying":"Ordinary Shares","underlying_shares":124373},"source":{"system":"sec-edgar","filing":"0001562180-24-004824","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024004824/primarydocument.xml","form_type":"4"}},{"id":1486744,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-06-07T20:06:56.000Z","date":"2024-06-05","kind":"exercise","planned":false,"acquired":true,"shares":124373,"price":22.82,"value":2838191.86,"ownership":{"direct":false,"nature":"The 2020 Groenhuysen Annuity Trust"},"balance_after":124373,"source":{"system":"sec-edgar","filing":"0001562180-24-004824","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024004824/primarydocument.xml","form_type":"4"}},{"id":1486707,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T16:25:28.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 6, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":1.04,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001494650-24-000087","document":"wk-form4_1717791920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000087/wk-form4_1717791920.xml","form_type":"4"}},{"id":1596150,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:09:41.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":1217,"price":16.01,"value":19484.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":251235,"source":{"system":"sec-edgar","filing":"0001562180-24-002248","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024002248/primarydocument.xml","form_type":"4"}},{"id":1596149,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:09:41.000Z","date":"2024-03-01","kind":"sale","planned":false,"acquired":false,"shares":2107,"price":16.0269,"value":33768.6783,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":252452,"source":{"system":"sec-edgar","filing":"0001562180-24-002248","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024002248/primarydocument.xml","form_type":"4"}},{"id":1609986,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-02-29T21:28:11.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":71920,"price":16.3,"value":1172296.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates."}],"balance_after":71920,"derivative":{"exercise_price":16.3,"exercise_date":"2025-02-27","expiration_date":"2034-02-26","underlying":"Ordinary Shares","underlying_shares":71920},"source":{"system":"sec-edgar","filing":"0001562180-24-001980","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001980/primarydocument.xml","form_type":"4"}},{"id":1609985,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-29T21:28:11.000Z","date":"2024-02-28","kind":"sale","planned":false,"acquired":false,"shares":2303,"price":16.1428,"value":37176.8684,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":254559,"source":{"system":"sec-edgar","filing":"0001562180-24-001980","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001980/primarydocument.xml","form_type":"4"}},{"id":1609984,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-29T21:28:11.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":47034,"price":16.3,"value":766654.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates."}],"balance_after":256862,"source":{"system":"sec-edgar","filing":"0001562180-24-001980","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001980/primarydocument.xml","form_type":"4"}},{"id":1609983,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-29T21:28:11.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":3,"price":12.69,"value":38.07,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023."}],"balance_after":209828,"source":{"system":"sec-edgar","filing":"0001562180-24-001980","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218024001980/primarydocument.xml","form_type":"4"}},{"id":1789185,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-09-05T20:24:18.000Z","date":"2023-09-01","kind":"sale","planned":false,"acquired":false,"shares":294,"price":21.8172,"value":6414.2568,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":209825,"source":{"system":"sec-edgar","filing":"0001562180-23-006683","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023006683/primarydocument.xml","form_type":"4"}},{"id":1833832,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-07-06T20:14:41.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":366,"price":35.28,"value":12912.48,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January1, 2023 through June 30, 2023.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023."}],"balance_after":210119,"source":{"system":"sec-edgar","filing":"0001562180-23-005761","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023005761/primarydocument.xml","form_type":"4"}},{"id":1860458,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T14:05:07.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":53500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 8, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":53500,"derivative":{"exercise_price":1.18,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":53500},"source":{"system":"sec-edgar","filing":"0001494650-23-000057","document":"wk-form4_1686333899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465023000057/wk-form4_1686333899.xml","form_type":"4"}},{"id":1965773,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:51:48.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":20415,"price":76.1594,"value":1554794.151,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":209753,"source":{"system":"sec-edgar","filing":"0001562180-23-002579","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002579/primarydocument.xml","form_type":"4"}},{"id":1965772,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:51:48.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":1692,"price":76.1594,"value":128861.7048,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":230168,"source":{"system":"sec-edgar","filing":"0001562180-23-002579","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002579/primarydocument.xml","form_type":"4"}},{"id":1965771,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:51:48.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":3528,"price":76.1594,"value":268690.3632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":231860,"source":{"system":"sec-edgar","filing":"0001562180-23-002579","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002579/primarydocument.xml","form_type":"4"}},{"id":1969093,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:40:52.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":3936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents vesting of performance-based restricted stock units."}],"balance_after":235388,"source":{"system":"sec-edgar","filing":"0001562180-23-002491","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002491/primarydocument.xml","form_type":"4"}},{"id":1969092,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:40:52.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":48050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents vesting of performance-based restricted stock units."}],"balance_after":231452,"source":{"system":"sec-edgar","filing":"0001562180-23-002491","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002491/primarydocument.xml","form_type":"4"}},{"id":1969091,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-06T21:40:52.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1213,"price":75.2779,"value":91312.0927,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":183402,"source":{"system":"sec-edgar","filing":"0001562180-23-002491","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000156218023002491/primarydocument.xml","form_type":"4"}},{"id":1979481,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2023-03-02T21:49:32.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":36013,"price":76.97,"value":2771920.61,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to buy 36,013 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates."}],"balance_after":36013,"derivative":{"exercise_price":76.97,"exercise_date":"2024-02-28","expiration_date":"2033-02-27","underlying":"Ordinary Shares","underlying_shares":36013},"source":{"system":"sec-edgar","filing":"0001645113-23-000025","document":"wf-form4_167779374758834.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000025/wf-form4_167779374758834.xml","form_type":"4"}},{"id":1979480,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-02T21:49:32.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":2164,"price":76.3624,"value":165248.2336,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":184615,"source":{"system":"sec-edgar","filing":"0001645113-23-000025","document":"wf-form4_167779374758834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000025/wf-form4_167779374758834.xml","form_type":"4"}},{"id":1979479,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-02T21:49:32.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":21653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":186779,"source":{"system":"sec-edgar","filing":"0001645113-23-000025","document":"wf-form4_167779374758834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000025/wf-form4_167779374758834.xml","form_type":"4"}},{"id":2057503,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2023-01-10T21:17:15.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":102,"price":62.305,"value":6355.11,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2022 through December 30, 2022.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022."}],"balance_after":165126,"source":{"system":"sec-edgar","filing":"0001645113-23-000013","document":"wf-form4_167338542046628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000013/wf-form4_167338542046628.xml","form_type":"4"}},{"id":2165638,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-09-06T21:14:18.000Z","date":"2022-09-02","kind":"sale","acquired":false,"shares":296,"price":79.037,"value":23394.952,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":165024,"source":{"system":"sec-edgar","filing":"0001645113-22-000076","document":"wf-form4_166249884466171.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000076/wf-form4_166249884466171.xml","form_type":"4"}},{"id":2210750,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:48:52.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":218,"price":59.075,"value":12878.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2022 through June 30, 2022.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022."}],"balance_after":165320,"source":{"system":"sec-edgar","filing":"0001645113-22-000063","document":"wf-form4_165723051770430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000063/wf-form4_165723051770430.xml","form_type":"4"}},{"id":2237736,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T10:15:24.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 8, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":32000,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001494650-22-000056","document":"wf-form4_165478411011044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465022000056/wf-form4_165478411011044.xml","form_type":"4"}},{"id":2277668,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-05-09T20:14:28.000Z","date":"2022-05-05","kind":"gift","acquired":true,"shares":1324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Currently exercisable."}],"balance_after":147048,"derivative":{"exercise_price":21.9,"expiration_date":"2026-01-12","underlying":"Ordinary Shares","underlying_shares":1324},"source":{"system":"sec-edgar","filing":"0001645113-22-000045","document":"wf-form4_165212724938002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000045/wf-form4_165212724938002.xml","form_type":"4"}},{"id":2277667,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-05-09T20:14:28.000Z","date":"2022-05-05","kind":"gift","acquired":false,"shares":1324,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Currently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By The 2020 Groenhuysen Annuity Trust.  Mr. Groenhuysen does not disclaim beneficial ownership."}],"balance_after":0,"derivative":{"exercise_price":21.9,"expiration_date":"2026-01-12","underlying":"Ordinary Shares","underlying_shares":1324},"source":{"system":"sec-edgar","filing":"0001645113-22-000045","document":"wf-form4_165212724938002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000045/wf-form4_165212724938002.xml","form_type":"4"}},{"id":2341913,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-09T21:52:30.000Z","date":"2022-03-08","kind":"sale","acquired":false,"shares":2923,"price":70.1,"value":204902.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":165102,"source":{"system":"sec-edgar","filing":"0001645113-22-000027","document":"wf-form4_164686273565625.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000027/wf-form4_164686273565625.xml","form_type":"4"}},{"id":2347767,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-03-07T23:16:09.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":7664,"price":80.59,"value":617641.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Options to buy 7,664 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates."}],"balance_after":7664,"derivative":{"exercise_price":80.59,"exercise_date":"2023-03-01","expiration_date":"2032-02-29","underlying":"Ordinary Shares","underlying_shares":7664},"source":{"system":"sec-edgar","filing":"0001645113-22-000015","document":"wf-form4_164669495236747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000015/wf-form4_164669495236747.xml","form_type":"4"}},{"id":2347766,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2022-03-07T23:16:09.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":38390,"price":80.59,"value":3093850.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Options to buy 38,390 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates."}],"balance_after":38390,"derivative":{"exercise_price":80.59,"exercise_date":"2023-03-01","expiration_date":"2032-02-29","underlying":"Ordinary Shares","underlying_shares":38390},"source":{"system":"sec-edgar","filing":"0001645113-22-000015","document":"wf-form4_164669495236747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000015/wf-form4_164669495236747.xml","form_type":"4"}},{"id":2347765,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:16:09.000Z","date":"2022-03-04","kind":"sale","acquired":false,"shares":2569,"price":70.407,"value":180875.583,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":168025,"source":{"system":"sec-edgar","filing":"0001645113-22-000015","document":"wf-form4_164669495236747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000015/wf-form4_164669495236747.xml","form_type":"4"}},{"id":2347764,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:16:09.000Z","date":"2022-03-03","kind":"sale","acquired":false,"shares":1301,"price":74.498,"value":96921.898,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":170594,"source":{"system":"sec-edgar","filing":"0001645113-22-000015","document":"wf-form4_164669495236747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000015/wf-form4_164669495236747.xml","form_type":"4"}},{"id":2347763,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-07T23:16:09.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":21921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates."}],"balance_after":171895,"source":{"system":"sec-edgar","filing":"0001645113-22-000015","document":"wf-form4_164669495236747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000015/wf-form4_164669495236747.xml","form_type":"4"}},{"id":2436834,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-01-12T22:30:22.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":75,"price":63.818,"value":4786.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 20121 through December 31, 2021.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021."}],"balance_after":149974,"source":{"system":"sec-edgar","filing":"0001645113-22-000003","document":"wf-form4_164202660712829.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000003/wf-form4_164202660712829.xml","form_type":"4"}},{"id":2577225,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-09-07T20:35:42.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":181,"price":138.232,"value":25019.992,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":149899,"source":{"system":"sec-edgar","filing":"0001645113-21-000107","document":"wf-form4_163104692257841.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000107/wf-form4_163104692257841.xml","form_type":"4"}},{"id":2605423,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2021-08-12T20:22:00.000Z","date":"2021-08-10","kind":"gift","acquired":false,"shares":320,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Indirect"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Currently exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By The 2020 Groenhuysen Annuity Trust. Mr. Groenhuysen does not disclaim beneficial ownership."}],"balance_after":1324,"derivative":{"exercise_price":21.9,"expiration_date":"2026-01-12","underlying":"Ordinary Shares","underlying_shares":320},"source":{"system":"sec-edgar","filing":"0001645113-21-000102","document":"wf-form4_162879970478058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000102/wf-form4_162879970478058.xml","form_type":"4"}},{"id":2605422,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2021-08-12T20:22:00.000Z","date":"2021-08-10","kind":"gift","acquired":true,"shares":320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Currently exercisable."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amended total to correct prior mathematical error."}],"balance_after":145724,"derivative":{"exercise_price":21.9,"expiration_date":"2026-01-12","underlying":"Ordinary Shares","underlying_shares":320},"source":{"system":"sec-edgar","filing":"0001645113-21-000102","document":"wf-form4_162879970478058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000102/wf-form4_162879970478058.xml","form_type":"4"}},{"id":2638086,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-07-08T21:34:52.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":66,"price":137.122,"value":9050.052,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of January 1, 2021 through June 30, 2021.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021."}],"balance_after":150080,"source":{"system":"sec-edgar","filing":"0001645113-21-000086","document":"wf-form4_162578004369784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000086/wf-form4_162578004369784.xml","form_type":"4"}},{"id":2673929,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-10T15:17:20.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":14439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 9, 2022 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2022 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":14439,"derivative":{"exercise_price":3.54,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":14439},"source":{"system":"sec-edgar","filing":"0001494650-21-000072","document":"wf-form4_162335262369937.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465021000072/wf-form4_162335262369937.xml","form_type":"4"}},{"id":2752933,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-04-08T20:18:19.000Z","date":"2020-02-28","kind":"sale","acquired":false,"shares":3670,"price":72.215,"value":265029.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on February 27, 2020 not previously reported.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":150014,"source":{"system":"sec-edgar","filing":"0001645113-21-000050","document":"wf-form4_161791308358699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000050/wf-form4_161791308358699.xml","form_type":"4"}},{"id":2797007,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-10T21:06:59.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":3004,"price":130.806,"value":392941.224,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":153684,"source":{"system":"sec-edgar","filing":"0001645113-21-000043","document":"wf-form4_161541040351233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000043/wf-form4_161541040351233.xml","form_type":"4"}},{"id":2803202,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-08T21:26:32.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":3854,"price":137.554,"value":530133.116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":156688,"source":{"system":"sec-edgar","filing":"0001645113-21-000040","document":"wf-form4_161523876525004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000040/wf-form4_161523876525004.xml","form_type":"4"}},{"id":2808845,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2021-03-04T22:50:32.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":23004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to buy 23,004 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates."}],"balance_after":23004,"derivative":{"exercise_price":153.09,"expiration_date":"2031-03-01","underlying":"Ordinary Shares","underlying_shares":23004},"source":{"system":"sec-edgar","filing":"0001645113-21-000029","document":"wf-form4_161489821134191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000029/wf-form4_161489821134191.xml","form_type":"4"}},{"id":2808844,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-04T22:50:32.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":12519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates."}],"balance_after":160542,"source":{"system":"sec-edgar","filing":"0001645113-21-000029","document":"wf-form4_161489821134191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000029/wf-form4_161489821134191.xml","form_type":"4"}},{"id":2808843,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-04T22:50:32.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":2392,"price":152.053,"value":363710.776,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Share Units vested on February 27, 2021.  This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":148023,"source":{"system":"sec-edgar","filing":"0001645113-21-000029","document":"wf-form4_161489821134191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000029/wf-form4_161489821134191.xml","form_type":"4"}},{"id":2820145,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T21:11:31.000Z","date":"2021-02-27","kind":"exercise","acquired":false,"shares":7715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2021-02-27","underlying":"Ordinary Shares","underlying_shares":7715},"source":{"system":"sec-edgar","filing":"0001645113-21-000020","document":"wf-form4_161471946713217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000020/wf-form4_161471946713217.xml","form_type":"4"}},{"id":2820144,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:11:31.000Z","date":"2021-02-27","kind":"exercise","acquired":true,"shares":7715,"price":149.1,"value":1150306.5,"ownership":{"direct":true},"balance_after":150415,"source":{"system":"sec-edgar","filing":"0001645113-21-000020","document":"wf-form4_161471946713217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000020/wf-form4_161471946713217.xml","form_type":"4"}},{"id":2912223,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-01-08T21:32:08.000Z","date":"2021-01-06","kind":"grant","acquired":true,"shares":93,"price":50.669,"value":4712.217,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan (\"ESPP\"), for the ESPP purchase period of July 1, 2020 through December 31, 2020.  This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2020."}],"balance_after":142700,"source":{"system":"sec-edgar","filing":"0001645113-21-000002","document":"wf-form4_161014151569340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511321000002/wf-form4_161014151569340.xml","form_type":"4"}},{"id":3026002,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":8262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.48,"expiration_date":"2024-02-25","underlying":"Ordinary Shares","underlying_shares":8262},"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3026001,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":200,"price":110.885,"value":22177.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $110.85 to $110.92.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3026000,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":1813,"price":110.24,"value":199865.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,813 shares in multiple trades at prices ranging from $109.84 to $110.66.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142807,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3025999,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":3536,"price":109.226,"value":386223.136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,536 shares in multiple trades at prices ranging from $108.84 to $109.82.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144620,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3025998,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":2513,"price":108.494,"value":272645.422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,513 shares in multiple trades at prices ranging from $107.84 to $108.83.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":148156,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3025997,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":200,"price":106.915,"value":21383.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 18, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $106.74 to $107.09.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":150669,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3025996,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-21T20:16:08.000Z","date":"2020-09-18","kind":"exercise","acquired":true,"shares":8262,"price":7.48,"value":61799.76,"ownership":{"direct":true},"balance_after":150869,"source":{"system":"sec-edgar","filing":"0001645113-20-000140","document":"wf-form4_160071932127330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000140/wf-form4_160071932127330.xml","form_type":"4"}},{"id":3027019,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"Fully vested as of the date hereof."}],"balance_after":8262,"derivative":{"exercise_price":7.48,"expiration_date":"2024-02-25","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027018,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"Fully vested as of the date hereof."}],"balance_after":20762,"derivative":{"exercise_price":7.48,"expiration_date":"2024-02-25","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027017,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":false,"shares":7579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":7579},"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027016,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":false,"shares":1933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":1933},"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027015,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":100,"price":110.52,"value":11052.0,"ownership":{"direct":true},"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027014,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":1500,"price":109.805,"value":164707.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,500 shares in multiple trades at prices ranging from $109.40 to $110.33.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142707,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027013,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":7868,"price":108.79,"value":855959.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 7,868 shares in multiple trades at prices ranging from $108.37 to $109.28.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144207,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027012,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":2232,"price":107.935,"value":240910.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,232 shares in multiple trades at prices ranging from $107.36 to $108.29.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":152075,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027011,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":500,"price":106.682,"value":53341.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 500 shares in multiple trades at prices ranging from $106.33 to $107.02.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":154307,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027010,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":300,"price":105.282,"value":31584.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"On September 17, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 300 shares in multiple trades at prices ranging from $104.83 to $105.82.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":154807,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027009,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-17","kind":"exercise","acquired":true,"shares":12500,"price":7.48,"value":93500.0,"ownership":{"direct":true},"balance_after":155107,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027008,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":600,"price":109.541,"value":65724.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 600 shares in multiple trades at prices ranging from $109.27 to $109.69.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027007,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":1700,"price":108.709,"value":184805.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,700 shares in multiple trades at prices ranging from $108.27 to $109.22.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":143207,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027006,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":5123,"price":107.663,"value":551557.549,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 5,123 shares in multiple trades at prices ranging from $107.24 to $108.20.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144907,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027005,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":3077,"price":106.67,"value":328223.59,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,077 shares in multiple trades at prices ranging from $106.24 to $107.23.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":150030,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027004,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":2000,"price":105.8,"value":211600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,000 shares in multiple trades at prices ranging from $105.24 to $106.24.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":153107,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027003,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":true,"shares":12500,"price":7.48,"value":93500.0,"ownership":{"direct":true},"balance_after":155107,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027002,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":400,"price":109.554,"value":43821.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 400 shares in multiple trades at prices ranging from $109.32 to $109.73.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027001,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":1000,"price":108.569,"value":108569.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,000 shares in multiple trades at prices ranging from $108.17 to $108.99.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":143007,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3027000,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":3279,"price":107.648,"value":352977.792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,279 shares in multiple trades at prices ranging from $107.13 to $108.09.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144007,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026999,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":2100,"price":106.549,"value":223752.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,100 shares in multiple trades at prices ranging from $106.13 to $107.08.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":147286,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026998,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":800,"price":105.616,"value":84492.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 800 shares in multiple trades at prices ranging from $104.98 to $105.93.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":149386,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026997,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":true,"shares":7579,"price":7.03,"value":53280.37,"ownership":{"direct":true},"balance_after":150186,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026996,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":200,"price":109.155,"value":21831.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 200 shares in multiple trades at prices ranging from $108.92 to $109.39.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026995,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":600,"price":107.974,"value":64784.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 600 shares in multiple trades at prices ranging from $107.78 to $108.21.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142807,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026994,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":633,"price":107.184,"value":67847.472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 633 shares in multiple trades at prices ranging from $106.78 to $107.56.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":143407,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026993,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"sale","acquired":false,"shares":500,"price":106.052,"value":53026.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 500 shares in multiple trades at prices ranging from $105.46 to $106.44.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144040,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3026992,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-18T20:37:31.000Z","date":"2020-09-16","kind":"exercise","acquired":true,"shares":1933,"price":7.03,"value":13588.99,"ownership":{"direct":true},"balance_after":144540,"source":{"system":"sec-edgar","filing":"0001645113-20-000139","document":"wf-form4_160046143094928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000139/wf-form4_160046143094928.xml","form_type":"4"}},{"id":3030246,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":7579,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030245,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":13368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":7.48,"expiration_date":"2024-02-25","underlying":"Ordinary Shares","underlying_shares":13368},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030244,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":1933,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030243,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":33262,"derivative":{"exercise_price":7.48,"expiration_date":"2024-02-25","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030242,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-14","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":14433,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030241,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Options to Buy Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-14","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Fully vested as of the date hereof."}],"balance_after":20079,"derivative":{"exercise_price":7.03,"expiration_date":"2023-02-19","underlying":"Ordinary Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030240,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":2334,"price":106.017,"value":247443.678,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F21","text":"On September 15, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,334 shares in multiple trades at prices ranging from $105.51 to $106.48.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":142607,"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}},{"id":3030239,"issuer":{"id":4494,"kind":"organization","name":"NovoCure Ltd"},"owners":[{"id":79466,"kind":"person","name":"GROENHUYSEN WILHELMUS CM","position":1,"cik":"0001264783","reported_name":"GROENHUYSEN WILHELMUS CM","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-09-16T21:24:54.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":10166,"price":104.685,"value":1064227.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F20","text":"On September 15, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 10,166 shares in multiple trades at prices ranging from $104.45 to $105.43.  The price reported above reflects the weighted average sale price.  Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":144941,"source":{"system":"sec-edgar","filing":"0001645113-20-000136","document":"wf-form4_160029147743039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511320000136/wf-form4_160029147743039.xml","form_type":"4"}}],"next_cursor":"2020-09-16T21:24:54.000000Z,3030239"}